Radiobiology Research Suite Expansion of the TriMetis GLP Vivarium at UTHSC

UTHSC 的 TriMetis GLP Vivarium 放射生物学研究套件扩建

基本信息

  • 批准号:
    10374310
  • 负责人:
  • 金额:
    $ 311.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-20 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

There is no radiation medical countermeasure (RCM) drug approved by the FDA that meets the criterion of a gastrointestinal (GI) or lung radiomitigator – an agent that mitigates GI acute radiation syndrome (GI-ARS) or lung-ARS when administered after the exposure. A critical barrier to progress in development of RCM drugs is that a traditional human clinical trial is not an option. Therefore, FDA approval of a RCM is done under their Animal Rule (21 CFR 314.600) that requires detailed understanding of its mechanism of action, demonstration of safety and efficacy in animal models, including nonhuman primates (NHP), and its safety in humans. The recent withdrawal of Altasciences Corp., the only GI-ARS qualified contract research organization from RCM preclinical testing has created a critical shortage and a national strategic vulnerability in qualified drug development sites in the USA. Although the NIH, DOD, BARDA, NASA and several pharmaceutical companies are intensively pursuing RCM development projects there is no domestic test site currently available with an established and validated NHP models for the evaluation of RCM drug candidates, particularly for GI-ARS. This is compounded by the US dependence on foreign (PR Chinese) suppliers of rhesus macaques. The University of Tennessee Health Sciences Center (UTHSC) has a unique resource: the TriMetis Life Sciences Animal Facility (TAF). Since 2016, TAF has been operated and managed by UTHSC under its PHS Assurance and AAALAC accredited program. The TAF is a state-of-the-art vivarium housing small- and large-animals, including nonhuman primates, operated under FDA-approved Good Laboratory Practice (GLP), thereby meeting the needs of academic and industry researchers both regionally and nationally. The purpose of this proposal is to equip TAF with an radiation biology suite suitable for development of radiation countermeasure (RCM), radioprotective and radiosensitizer drugs under the Animal Rule. Installation of an irradiation suite at TAF will have a significant impact beyond the needs of RCM drug development: it will be optimal for the evaluation of radiotherapy sensitizers for cancer treatment, including general preclinical research, and drug testing with toxicology and pharmacokinetic studies. The UTHSC-owned Plough Center for Sterile Drug Delivery, where GMP manufacturing and compounding of test articles is done, the Regional Biocontainment Laboratory, where GLP radiation injury rodent models have already been in operation, are within a few hundred feet of the TAF and provide an unparalleled comprehensive drug development infrastructure that will meet all national academic and industry research and drug regulatory approval needs. The new state-of-the-art facility also develop domestically bred cynomolgus monkey radiation models thereby eliminating the US dependence on foreign suppliers.
目前还没有 FDA 批准的符合放射医学对抗(RCM)标准的放射医学对抗(RCM)药物 胃肠道 (GI) 或肺部放射缓解剂 – 缓解胃肠道急性放射综合征 (GI-ARS) 或 暴露后施用肺-ARS。 RCM 药物开发进展的关键障碍 传统的人体临床试验不是一种选择。因此,FDA 对 RCM 的批准是根据其规定进行的 动物规则 (21 CFR 314.600),需要详细了解其作用机制、演示 动物模型(包括非人类灵长类动物(NHP))的安全性和有效性及其对人类的安全性。这 最近,唯一一家具有 GI-ARS 资格的合同研究机构 Altasciences Corp. 从 RCM 中退出 临床前试验造成合格药品严重短缺和国家战略脆弱性 美国的开发地点。尽管 NIH、DOD、BARDA、NASA 和多家制药公司 正在大力开展 RCM 开发项目,目前国内尚无具备 建立并验证了 NHP 模型,用于评估 RCM 候选药物,特别是 GI-ARS。 美国对外国(中国)恒河猴供应商的依赖使情况更加复杂。这 田纳西大学健康科学中心 (UTHSC) 拥有独特的资源:TriMetis 生命科学 动物设施(TAF)。自 2016 年以来,TAF 一直由 UTHSC 在其 PHS 保障下运营和管理 和 AAALAC 认证计划。 TAF 是一个最先进的动物园,饲养着小型和大型动物, 包括非人类灵长类动物,根据 FDA 批准的良好实验室规范 (GLP) 进行操作,从而满足 地区和国家学术和行业研究人员的需求。本提案的目的 为TAF配备适合开发辐射对抗措施的辐射生物学套件 (RCM)、动物规则下的放射防护和放射增敏药物。安装辐照套件 TAF 将产生超出 RCM 药物开发需求的重大影响:这将是最佳选择 癌症治疗放疗增敏剂的评估,包括一般临床前研究和药物 毒理学和药代动力学研究测试。 UTHSC 拥有的 Plough 无菌药物输送中心, 区域生物防护实验室是进行 GMP 生产和测试物品配制的地方, GLP 辐射损伤啮齿动物模型已经投入使用,距离辐射源几百英尺。 TAF 并提供无与伦比的综合药物开发基础设施,以满足所有国家的需求 学术和行业研究以及药物监管审批需求。新的最先进的设施还 开发国产食蟹猴辐射模型,从而消除对美国的依赖 关于国外供应商。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GABOR J TIGYI其他文献

GABOR J TIGYI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GABOR J TIGYI', 18)}}的其他基金

IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator
Radioprotectin 1 的 IND 开发:双重 GI/HE 辐射缓解剂
  • 批准号:
    10794519
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator
Radioprotectin 1 的 IND 开发:双重 GI/HE 辐射缓解剂
  • 批准号:
    10401460
  • 财政年份:
    2020
  • 资助金额:
    $ 311.53万
  • 项目类别:
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator
Radioprotectin 1 的 IND 开发:双重 GI/HE 辐射缓解剂
  • 批准号:
    10845827
  • 财政年份:
    2020
  • 资助金额:
    $ 311.53万
  • 项目类别:
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator
Radioprotectin 1 的 IND 开发:双重 GI/HE 辐射缓解剂
  • 批准号:
    10194368
  • 财政年份:
    2020
  • 资助金额:
    $ 311.53万
  • 项目类别:
IND-Enabling Preclinical Development of a New Radiomitigator
IND 促进新型放射缓解剂的临床前开发
  • 批准号:
    9280853
  • 财政年份:
    2013
  • 资助金额:
    $ 311.53万
  • 项目类别:
IND-Enabling Preclinical Development of a New Radiomitigator
IND 促进新型放射缓解剂的临床前开发
  • 批准号:
    9064077
  • 财政年份:
    2013
  • 资助金额:
    $ 311.53万
  • 项目类别:
IND-Enabling Preclinical Development of a New Radiomitigator
IND 促进新型放射缓解剂的临床前开发
  • 批准号:
    8842923
  • 财政年份:
    2013
  • 资助金额:
    $ 311.53万
  • 项目类别:
Analysis of Radiomitigative Cell Signaling
放射抑制细胞信号传导分析
  • 批准号:
    8476331
  • 财政年份:
    2012
  • 资助金额:
    $ 311.53万
  • 项目类别:
Novel Radiomitigators Targeting LPA Receptors
针对 LPA 受体的新型放射缓解剂
  • 批准号:
    8760294
  • 财政年份:
    2012
  • 资助金额:
    $ 311.53万
  • 项目类别:
Novel Radiomitigators Targeting LPA Receptors
针对 LPA 受体的新型放射缓解剂
  • 批准号:
    8963438
  • 财政年份:
    2012
  • 资助金额:
    $ 311.53万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 311.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了